Skip to main content
IPO brings in $7.1M for Co-Diagnostics

An initial public offering of over 1.1 million shares on the Nasdaq Capital Market pulled in $7.1 million in gross proceeds for Co-Diagnostics. Net proceeds will be used as working capital, as well as to support test development, in-field test performance assessment and validation, regulatory submissions for diagnostic tests, laboratory facilities expansion and general corporate functions.

Full Story: